Angiochem receives NBTS innovation award for development of new brain cancer treatments Feb. 23, 2011
Promising phase II data on cabozantinib in patients with prostate cancer and soft tissue disease Feb. 22, 2011
Initial doses of TRC-105 are tolerated in patients with castration-resistant prostate cancer Feb. 22, 2011
RSS